Profile data is unavailable for this security.
About the company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
- Revenue in USD (TTM)2.12bn
- Net income in USD339.20m
- Incorporated1996
- Employees1.50k
- LocationNeurocrine Biosciences Inc6027 EDGEWOOD BEND COURTSAN DIEGO 92130United StatesUSA
- Phone+1 (858) 617-7600
- Fax+1 (858) 617-7602
- Websitehttps://www.neurocrine.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viking Therapeutics Inc | 0.00 | -96.75m | 7.55bn | 28.00 | -- | 8.20 | -- | -- | -0.9379 | -0.9379 | 0.00 | 8.31 | 0.00 | -- | -- | 0.00 | -14.36 | -21.91 | -14.78 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Exelixis Inc | 2.01bn | 349.99m | 7.65bn | 1.31k | 22.98 | 3.61 | 20.33 | 3.80 | 1.17 | 1.17 | 6.54 | 7.43 | 0.6809 | 3.23 | 6.40 | 1,537,386.00 | 11.83 | 8.86 | 13.38 | 9.91 | 96.06 | 96.30 | 17.38 | 15.43 | 4.21 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Revolution Medicines Inc | 742.00k | -519.21m | 7.71bn | 443.00 | -- | 4.73 | -- | 10,396.04 | -3.65 | -3.65 | 0.0051 | 9.77 | 0.0005 | -- | 0.5912 | 1,962.96 | -36.03 | -29.76 | -38.48 | -32.59 | -- | -- | -69,973.99 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Tempus AI Inc | 595.57m | -790.20m | 7.73bn | 2.30k | -- | 78.67 | -- | 12.98 | -8.23 | -8.23 | 4.34 | 0.6367 | -- | -- | -- | -- | -- | -- | -- | -- | 51.85 | -- | -121.04 | -- | 3.52 | -28.75 | 0.8183 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
Legend Biotech Corp (ADR) | 455.99m | -285.01m | 9.31bn | 2.20k | -- | 8.03 | -- | 20.42 | -1.57 | -1.57 | 2.51 | 6.33 | 0.2446 | 10.63 | 32.42 | 253,328.30 | -15.29 | -37.71 | -17.63 | -47.19 | 60.28 | -- | -62.50 | -286.51 | 4.78 | -16.63 | 0.2263 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Charles River Lbrtrs ntrntl Inc | 4.08bn | 431.79m | 10.82bn | 20.00k | 25.04 | 2.91 | 13.94 | 2.65 | 8.37 | 8.37 | 78.94 | 72.13 | 0.5188 | 8.23 | 5.22 | 203,888.80 | 5.67 | 6.46 | 6.52 | 7.62 | 35.98 | 36.99 | 10.93 | 11.58 | 1.21 | 4.97 | 0.39 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Medpace Holdings Inc | 2.03bn | 339.64m | 11.45bn | 5.80k | 34.71 | 14.95 | 31.11 | 5.64 | 10.63 | 10.63 | 63.59 | 24.69 | 1.22 | -- | 7.05 | 344,075.90 | 20.43 | 13.94 | 45.87 | 23.18 | 28.52 | 28.84 | 16.74 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
Sarepta Therapeutics Inc | 1.50bn | 47.30m | 12.12bn | 1.31k | 304.96 | 11.24 | 139.23 | 8.05 | 0.4168 | 0.4168 | 15.40 | 11.30 | 0.4595 | 0.4948 | 5.04 | 1,145,352.00 | 1.44 | -21.63 | 1.76 | -25.75 | 88.29 | 86.65 | 3.14 | -77.05 | 3.19 | -- | 0.5324 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Neurocrine Biosciences, Inc. | 2.12bn | 339.20m | 12.16bn | 1.50k | 36.37 | 4.84 | 33.43 | 5.74 | 3.31 | 3.31 | 20.64 | 24.87 | 0.7163 | 0.9811 | 4.95 | 1,513,929.00 | 11.46 | 9.77 | 13.74 | 12.19 | 98.28 | 98.51 | 16.00 | 14.79 | 4.08 | 6.10 | 0.00 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
BIO-TECHNE Corp | 1.16bn | 168.07m | 12.75bn | 3.10k | 76.79 | 6.15 | 45.56 | 11.00 | 1.05 | 1.05 | 7.20 | 13.08 | 0.4339 | 2.22 | 5.04 | 373,890.30 | 6.29 | 9.42 | 6.65 | 10.04 | 66.41 | 67.29 | 14.50 | 21.41 | 2.75 | 13.32 | 0.1336 | 22.79 | 1.97 | 10.17 | -41.07 | 11.86 | 19.87 | 0.00 |
Insmed Inc | 328.61m | -802.69m | 12.88bn | 912.00 | -- | 321.89 | -- | 39.21 | -5.40 | -5.40 | 2.22 | 0.2329 | 0.2023 | 0.8789 | 9.22 | 360,312.50 | -49.41 | -40.96 | -63.68 | -46.88 | 77.61 | 77.99 | -244.27 | -212.92 | 2.53 | -14.67 | 0.9687 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
Exact Sciences Corp | 2.61bn | -175.01m | 13.09bn | 6.50k | -- | 4.10 | 341.06 | 5.01 | -0.9607 | -0.9607 | 14.28 | 17.29 | 0.401 | 5.43 | 11.81 | 401,847.80 | -2.69 | -9.71 | -2.95 | -10.60 | 73.19 | 74.10 | -6.70 | -28.21 | 1.98 | -- | 0.4478 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
Vaxcyte Inc | 0.00 | -497.19m | 15.56bn | 254.00 | -- | 6.52 | -- | -- | -4.62 | -4.62 | 0.00 | 17.96 | 0.00 | -- | -- | 0.00 | -27.70 | -34.22 | -28.85 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
United Therapeutics Corporation | 2.62bn | 1.07bn | 15.63bn | 1.17k | 16.15 | 2.74 | 13.83 | 5.97 | 21.75 | 21.75 | 53.16 | 128.25 | 0.3904 | 2.43 | 9.29 | 2,240,325.00 | 15.96 | 10.38 | 17.53 | 11.27 | 88.85 | 91.47 | 40.87 | 29.25 | 4.18 | -- | 0.0807 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 30 Jun 2024 | 10.91m | 10.81% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 9.90m | 9.81% |
SSgA Funds Management, Inc.as of 30 Jun 2024 | 4.61m | 4.56% |
Renaissance Technologies LLCas of 30 Jun 2024 | 2.47m | 2.44% |
Bellevue Asset Management AGas of 30 Jun 2024 | 1.90m | 1.88% |
Geode Capital Management LLCas of 30 Jun 2024 | 1.82m | 1.80% |
JPMorgan Investment Management, Inc.as of 30 Jun 2024 | 1.82m | 1.80% |
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 1.71m | 1.70% |
Dodge & Coxas of 30 Jun 2024 | 1.28m | 1.27% |
AQR Capital Management LLCas of 30 Jun 2024 | 1.22m | 1.21% |